Skip to main content

Table 1 Demographic characteristics and baseline modifiable risk factors of the population included in the model

From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

Variable

Mean (± Standard error)

Distribution

References

Demographics

  Age (years)

63.8 (0.052)

Normal

[17]

  Female (%)

37 (7.5a)

Normal

[9]

  Duration of diabetes (years)

10.5 (0.5)

Normal

[9]

  Height (m)

1.65 (0.33a)

Normal

[19]

Modifiable risk factors

  HbA1c (%)

8.3 (0.009)

Normal

[17]

  SBP (mmHg)

140.3 (28.1a)

Normal

[19]

  Weight (kg)

92.0 (18.4a)

Normal

[19]

  eGFR (ml/min/1.73m2)

85.2 (0.15)

Normal

[9]

CVD History

  Peripheral artery disease (%)

6.0 (0.1)

Normal

[9]

  CHF (%)

5.5 (1.1a)

Normal

[20]

  1. aStandard error assumed 20% of the mean
  2. CHF congestive heart failure, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, SBP systolic blood pressure